Combining 3-D Quantitative Structure-Activity Relationship with Ligand Based and Structure Based Alignment Procedures for in Silico Screening of New Hepatitis C Virus NS5B Polymerase Inhibitors
暂无分享,去创建一个
Neerja Kaushik-Basu | Ira Musmuca | Antonia Caroli | Antonello Mai | Payal Arora | Rino Ragno | A. Mai | Neerja Kaushik-Basu | R. Ragno | P. Arora | Ira Musmuca | Antonia Caroli
[1] Roger J.-B. Wets,et al. Minimization by Random Search Techniques , 1981, Math. Oper. Res..
[2] Meitian Wang,et al. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition. , 2006, Journal of molecular biology.
[3] G. Cruciani,et al. Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .
[4] Neerja Kaushik-Basu,et al. Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors , 2008, Nucleic acids research.
[5] Uwe Koch,et al. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. , 2007, Current topics in medicinal chemistry.
[6] Ajay N. Jain,et al. Physical binding pocket induction for affinity prediction. , 2009, Journal of medicinal chemistry.
[7] Holger Gohlke,et al. The Amber biomolecular simulation programs , 2005, J. Comput. Chem..
[8] Volker Brass,et al. Recent developments in target identification against hepatitis C virus , 2004, Expert opinion on therapeutic targets.
[9] M. Houghton,et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.
[10] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[11] Jeffrey A Pfefferkorn,et al. Inhibitors of HCV NS5B polymerase. Part 1: Evaluation of the southern region of (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid. , 2005, Bioorganic & medicinal chemistry letters.
[12] Gary Larson,et al. Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure. , 2007, Bioorganic & medicinal chemistry letters.
[13] Neerja Kaushik-Basu,et al. Thiazolidinones : a novel class of hepatitis C virus NS 5 B polymerase inhibitors , 2008 .
[14] J. Hoofnagle,et al. Mechanism of action of interferon and ribavirin in treatment of hepatitis C , 2005, Nature.
[15] Garland R Marshall,et al. Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening. , 2008, Journal of medicinal chemistry.
[16] Meitian Wang,et al. Non-nucleoside Analogue Inhibitors Bind to an Allosteric Site on HCV NS5B Polymerase , 2003, The Journal of Biological Chemistry.
[17] Fabrizio Manetti,et al. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies. , 2005, Journal of medicinal chemistry.
[18] Uwe Koch,et al. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. , 2006, Infectious disorders drug targets.
[19] George Burton,et al. Identification of small molecule inhibitors of the hepatitis C virus RNA-dependent RNA polymerase from a pyrrolidine combinatorial mixture. , 2005, Bioorganic & medicinal chemistry letters.
[20] A. Mai,et al. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. , 2004, Journal of medicinal chemistry.
[21] R. Shoemaker,et al. Identification of polymerase and processivity inhibitors of vaccinia DNA synthesis using a stepwise screening approach. , 2008, Antiviral research.
[22] Hui Li,et al. Identification and structure-based optimization of novel dihydropyrones as potent HCV RNA polymerase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.
[23] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..
[24] G. Cruciani,et al. Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. , 1994, Journal of medicinal chemistry.
[25] Ricardo Macarron,et al. Identification and Biological Characterization of Heterocyclic Inhibitors of the Hepatitis C Virus RNA-dependent RNA Polymerase* , 2002, The Journal of Biological Chemistry.
[26] J. Hoofnagle,et al. Hepatitis C: The clinical spectrum of disease , 1997, Hepatology.
[27] Yvonne Jones,et al. High resolution structures of HIV-1 RT from four RT–inhibitor complexes , 1995, Nature Structural Biology.
[28] S. Wold,et al. Comparative molecular field analysis , 1991 .
[29] Gary Larson,et al. Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: convergence of structure-based drug design and X-ray crystallographic study. , 2007, Bioorganic & medicinal chemistry letters.
[30] Ajay N. Jain,et al. Ligand-based structural hypotheses for virtual screening. , 2004, Journal of medicinal chemistry.
[31] M. Alter,et al. Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.
[32] M. Fried,et al. Side effects of therapy of hepatitis C and their management , 2002, Hepatology.
[33] Robert A. Love,et al. Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme , 2003, Journal of Virology.
[34] Denis Labrecque,et al. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides. , 2004, Bioorganic & medicinal chemistry letters.
[35] Ajay N. Jain,et al. Robust ligand-based modeling of the biological targets of known drugs. , 2006, Journal of medicinal chemistry.
[36] R. Cramer,et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.
[37] P. Goodford. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.
[38] Jonathan B. Chaires,et al. Discovery of novel triple helical DNA intercalators by an integrated virtual and actual screening platform , 2009, Nucleic acids research.
[39] R. De Francesco,et al. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. , 2007, Advanced drug delivery reviews.
[40] F. Rey,et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[41] Charles A. Lesburg,et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site , 1999, Nature Structural Biology.
[42] Dashyant Dhanak,et al. 3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase. , 2006, Journal of medicinal chemistry.
[43] Darius Bilimoria,et al. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides. , 2004, Bioorganic & medicinal chemistry letters.
[44] D S Goodsell,et al. Automated docking of flexible ligands: Applications of autodock , 1996, Journal of molecular recognition : JMR.
[45] Peter A. Kollman,et al. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .
[46] N. Walker,et al. SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. , 2006, Journal of medicinal chemistry.
[47] M. Pastor,et al. A strategy for the incorporation of water molecules present in a ligand binding site into a three-dimensional quantitative structure--activity relationship analysis. , 1997, Journal of medicinal chemistry.
[48] Lawrence C Kuo,et al. Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs* , 2003, The Journal of Biological Chemistry.
[49] Satoru Ikeda,et al. Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors. , 2006, Journal of medicinal chemistry.
[50] Giovanni Migliaccio,et al. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. , 2003, Antiviral research.
[51] M Pastor,et al. Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. , 1997, Journal of medicinal chemistry.
[52] David Haigh,et al. Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate. , 2007, Journal of medicinal chemistry.
[53] S. Wold,et al. PLS: Partial Least Squares Projections to Latent Structures , 1993 .
[54] Darius Bilimoria,et al. Identification of N,N-disubstituted phenylalanines as a novel class of inhibitors of hepatitis C NS5B polymerase. , 2003, Journal of medicinal chemistry.
[55] Gary Larson,et al. Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors. , 2006, Bioorganic & medicinal chemistry letters.
[56] Krzysztof Kuczera,et al. Are L-adenosine and its derivatives substrates for S-adenosyl-L-homocysteine hydrolase? , 2005, Journal of medicinal chemistry.
[57] Maurizio Botta,et al. A Multidisciplinary Approach for the Identification of Novel HIV‐1 Non‐Nucleoside Reverse Transcriptase Inhibitors: S‐DABOCs and DAVPs , 2008, ChemMedChem.
[58] Uwe Koch,et al. Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site* , 2005, Journal of Biological Chemistry.
[59] Nahum Sonenberg,et al. Hepatitis C therapeutics: current status and emerging strategies , 2002, Nature Reviews Drug Discovery.
[60] Conrad C. Huang,et al. Tools for integrated sequence-structure analysis with UCSF Chimera , 2006, BMC Bioinformatics.
[61] Richard Nugent,et al. Inhibitors of HCV NS5B polymerase. Part 2: Evaluation of the northern region of (2Z)-2-benzoylamino-3-(4-phenoxy-phenyl)-acrylic acid. , 2005, Bioorganic & medicinal chemistry letters.
[62] N. Walker,et al. Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases. , 2006, Journal of molecular biology.
[63] C. Rice,et al. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. , 2000, Current topics in microbiology and immunology.
[64] Rajiv Chopra,et al. Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site. , 2006, Journal of medicinal chemistry.
[65] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..